Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (ACIU) is a Swiss clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases like Alzheimer's. This page provides investors and researchers with centralized access to official news, financial disclosures, and scientific developments directly from the company.
Key resources include earnings reports, clinical trial updates, strategic collaborations, and regulatory milestones. Stay informed on ACIU's progress in developing diagnostic tools and therapies targeting protein misfolding pathologies through its proprietary platforms.
Content spans pipeline advancements, peer-reviewed research highlights, and material business events. Bookmark this page to efficiently track ACIU's contributions to neuroscience innovation and make data-driven decisions based on verified company communications.
AC Immune (NASDAQ: ACIU) has secured a €1.45M grant from the EU's Joint Programme – Neurodegenerative Disease Research (JPND). This funding will support the development of the first-in-class TDP-43 PET tracer in collaboration with the JPND ImageTDP-43 consortium, aimed at detecting neurodegenerative diseases including ALS and FTLD-TDP. The company emphasizes its innovative Morphomer™ platform's role in advancing precision medicine, as highlighted by CEO Prof. Andrea Pfeifer. The TDP-43 PET tracer shows strong binding to pathological aggregates, enhancing diagnostics and potential treatments for Alzheimer’s disease.
AC Immune (NASDAQ: ACIU) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020. CEO Prof. Andrea Pfeifer will present the company’s advanced anti-Tau clinical pipeline, which includes an antibody, a small molecule inhibitor, and a vaccine targeting neurodegenerative diseases. The presentation will highlight recent results from their Tau PET imaging agent, PI-2620, which may aid in earlier diagnosis of progressive supranuclear palsy (PSP). Four clinical-stage assets are in development.
AC Immune SA (NASDAQ: ACIU) announced the start of investigational new drug (IND)-enabling studies for its first-in-class anti-TDP-43 antibody, which is the only antibody reported to have in vivo activity against TDP-43 neuropathology. This antibody targets various neurodegenerative conditions, including ALS and FTLD-TDP, associated with significant market potential. The initiative follows several key achievements in the company’s pipeline, which utilizes the proprietary SupraAntigen™ and Morphomer™ platforms. CEO Andrea Pfeifer emphasized the importance of this milestone in addressing unmet needs in neurodegenerative diseases.
AC Immune (NASDAQ: ACIU) presented innovative data for its next-generation alpha-synuclein PET tracer at the Alzheimer’s Association International Conference (AAIC) on July 28, 2020. The preclinical results highlight improved contrast and specificity for diagnosing Parkinson’s disease, meeting a significant clinical need. The company’s Morphomer™ platform is key to developing these diagnostics. ACI-12589 shows promise as a first-class imaging agent, advancing the company's therapeutic and diagnostic strategies for neurodegenerative diseases, particularly alpha-synucleinopathies.
AC Immune (NASDAQ: ACIU) announced that it will deliver two oral presentations at the Alzheimer’s Association International Conference (AAIC), running virtually from July 27 to 31, 2020. The presentations will cover the company's advancements in the alpha-synuclein PET tracer program and the Phase 1b trial of the ACI-24 anti-Abeta vaccine in Down syndrome. These presentations highlight AC Immune’s innovative pipeline targeting neurodegenerative diseases and confirm its commitment to pioneering diversified approaches in Alzheimer’s treatment.
AC Immune SA (NASDAQ: ACIU) has advanced to the second highest dosing group in its Phase 1b/2a clinical trial for ACI-35.030, an investigational vaccine targeting Alzheimer’s disease. This decision follows promising interim results showing safety, tolerability, and immunogenicity. ACI-35.030 aims to generate an antibody response against pathological phospho-Tau proteins, potentially mitigating Tau pathology. The trial will assess safety, tolerability, and clinical outcomes over 48 weeks. This vaccine builds on previous successes and is developed in collaboration with Janssen Pharmaceuticals.
AC Immune SA (NASDAQ: ACIU) and Life Molecular Imaging announced the publication of clinical results for the Tau-PET tracer PI-2620, showing its potential in diagnosing progressive supranuclear palsy (PSP). Published in JAMA Neurology, the study indicates that PI-2620 allows improved detection of Tau protein deposits associated with PSP, potentially leading to earlier and more accurate diagnoses. The tracer has already exhibited effectiveness in detecting Tau pathology in Alzheimer's disease. This development enhances the diagnostic capabilities for neurodegenerative disorders and could influence future therapeutic interventions.
AC Immune (NASDAQ: ACIU) announced that shareholders approved all resolutions at the Annual General Meeting held on June 26, 2020, in Lausanne, Switzerland. Board members including Douglas Williams and Martin Velasco were re-elected. The company is progressing on five clinical readouts in 2020, particularly a Phase 2 trial for its anti-Tau antibody, semorinemab, in Alzheimer's disease. Additionally, AC Immune reported a robust financial position, fully funded through Q1 2024, and has successfully adapted its operations during the Covid-19 outbreak, maintaining workflow continuity.
AC Immune SA (NASDAQ: ACIU) announced participation at the UBS Virtual Global Healthcare Conference scheduled for May 20, 2020. CEO Prof. Andrea Pfeifer will present advancements in therapies targeting TDP-43 and alpha-synuclein, key players in neurodegenerative diseases such as Alzheimer's and Parkinson's. The company highlights its proprietary platforms, SupraAntigen™ and Morphomer™, which drive innovations in therapeutics and diagnostics. AC Immune aims to enhance early diagnosis and treatment precision in neurodegenerative disorders, supported by collaborations with major pharmaceutical companies.
